Litigation Details for Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)
✉ Email this page to a colleague
Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-04-01 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Plaintiff | Referred To | Sherry R. Fallon |
| Parties | LUPIN PHARMACEUTICALS, INC. | ||
| Patents | 10,179,140; 9,603,860 | ||
| Attorneys | Megan A. Chacon | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Exeltis USA, Inc. v. Lupin Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Exeltis USA, Inc. v. Lupin Ltd. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-03-01 | 107 | Opinion - Memorandum Opinion | U.S. Patent No. 9,603,860 (the “’860 patent”), U.S. Patent No. 10,179,140 (the “’140 patent”), U.…construction for multiple terms in U.S. Patent Nos. 9,603,860, 10,179,140, 10,987,364, 11,123,299, 11,291,632…U.S. Patent No. 10,987,364 (the “’364 patent”), U.S. Patent No. 11,123,299 (the “’299 patent”), U.…U.S. Patent No. 11,291,632 (the “’632 patent”), U.S. Patent No. 11,291,633 (the “’633 patent”), U.…U.S. Patent No. 11,351,122 (the “’122 patent”), U.S. Patent No. 11,413,249 (the “’249 patent”), U. | External link to document |
| 2022-06-06 | 15 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s): 9,603,860; 10,179,140; 10,603,281;… 1 April 2022 1:22-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
| 2023-08-17 | 219 | Notice of Service | Amended Invalidity Contentions for U.S. Patent Nos. 9,603,860; 10,179,140; 10,987,364; 11,123,299; 11,291,632… 1 April 2022 1:22-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
| 2024-02-20 | 298 | Opinion - Memorandum Opinion | the '487 patent"), 11,413,249 ("the ' 249 patent", and 10,179,140 ("the &#…in U.S. Patent Nos. 11,123,299, 11,291,632, 11,351,122, 11,478,487, 11,413,249, and 10,179,140 (see Memorandum…x27;299 patent, claim 14; '632 patent, claims 12 and 21; '12 patent, claim 29; '… ('299 patent, claim 14; '632 patent, claims 12 and 2r '487 patent, claim 19) …of multi pl terms in U.S. Patent Nos. 11 ,123,299 ("the '299 patent"), 11,291,632 (" | External link to document |
| 2024-02-21 | 302 | Letter | U.S. Patent No. 11,491,113 (the “’113 Patent”) in lieu of claim 33 of U.S. Patent No. 10,179,140 Patent…Patent (the “’140 Patent”), currently asserted by Exeltis, for good cause as shown here.1 In light of the…intends to stipulate to noninfringement of the ’140 Patent. Exeltis is prejudiced by this late-stage claim… time stipulated to noninfringement of the ’140 patent and would have had an opportunity to pursue a different…three invalidity defenses for claim 16 of the ’113 Patent from those previously identified for this claim | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
